Fisher, Michael J. http://orcid.org/0000-0003-3408-3839
Shih, Chie-Schin
Rhodes, Steven D.
Armstrong, Amy E.
Wolters, Pamela L.
Dombi, Eva
Zhang, Chi
Angus, Steven P.
Johnson, Gary L.
Packer, Roger J.
Allen, Jeffrey C.
Ullrich, Nicole J.
Goldman, Stewart
Gutmann, David H.
Plotkin, Scott R.
Rosser, Tena
Robertson, Kent A.
Widemann, Brigitte C.
Smith, Abbi E.
Bessler, Waylan K.
He, Yongzheng
Park, Su-Jung
Mund, Julie A.
Jiang, Li
Bijangi-Vishehsaraei, Khadijeh
Robinson, Coretta Thomas
Cutter, Gary R.
Korf, Bruce R.
Shih, Chie-Schin
Armstrong, Amy E.
Blakeley, Jaishri O.
Clapp, D. Wade
,
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (U54-CA196519-04)
U.S. Department of Health & Human Services | NIH | Eunice Kennedy Shriver National Institute of Child Health and Human Development (K12-HD000850)
Exelixis
Article History
Received: 19 December 2019
Accepted: 25 November 2020
First Online: 13 January 2021
Competing interests
: The authors declare the following competing interests: C.-S.S. is currently employed at Merck Research Laboratories (MRL) within Merck and Co. in Late Stage Oncology Clinical Development and is a consultant for the Selumetinib NF program at MRL. P.L.W. has holdings in Bristol-Myers Squibb under the amount allowable by the NIH. The remaining authors have no competing interests to declare.